360 related articles for article (PubMed ID: 23955273)
1. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
Clozel T; Yang S; Elstrom RL; Tam W; Martin P; Kormaksson M; Banerjee S; Vasanthakumar A; Culjkovic B; Scott DW; Wyman S; Leser M; Shaknovich R; Chadburn A; Tabbo F; Godley LA; Gascoyne RD; Borden KL; Inghirami G; Leonard JP; Melnick A; Cerchietti L
Cancer Discov; 2013 Sep; 3(9):1002-19. PubMed ID: 23955273
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic approaches for chemosensitization of refractory diffuse large B-cell lymphomas.
Steinhardt JJ; Gartenhaus RB
Cancer Discov; 2013 Sep; 3(9):968-70. PubMed ID: 24019329
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
Pera B; Tang T; Marullo R; Yang SN; Ahn H; Patel J; Elstrom R; Ruan J; Furman R; Leonard J; Cerchietti L; Martin P
Clin Epigenetics; 2016; 8():79. PubMed ID: 27453763
[TBL] [Abstract][Full Text] [Related]
4. Epigenetics: Showing a more sensitive side.
McCarthy N
Nat Rev Cancer; 2013 Oct; 13(10):680. PubMed ID: 24030504
[No Abstract] [Full Text] [Related]
5. Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
Leshchenko VV; Kuo PY; Jiang Z; Thirukonda VK; Parekh S
Clin Cancer Res; 2014 Jan; 20(2):382-92. PubMed ID: 24178621
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
Martin P; Bartlett NL; Chavez JC; Reagan JL; Smith SM; LaCasce AS; Jones J; Drew J; Wu C; Mulvey E; Revuelta MV; Cerchietti L; Leonard JP
Blood; 2022 Feb; 139(8):1147-1159. PubMed ID: 34428285
[TBL] [Abstract][Full Text] [Related]
7. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
8. Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma.
Stelling A; Wu CT; Bertram K; Hashwah H; Theocharides APA; Manz MG; Tzankov A; Müller A
Blood Adv; 2019 Oct; 3(20):3020-3032. PubMed ID: 31648327
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation of PTPL1, PTPN6, DAPK, p16 and 5-azacitidine inhibits growth in DLBCL.
Wang W; Wang J; Li Z; Zhu M; Zhang Z; Wang Y; Jing H
Oncol Rep; 2016 Jan; 35(1):139-46. PubMed ID: 26498513
[TBL] [Abstract][Full Text] [Related]
10. 5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.
Wang W; Wang J; Li M; Ying J; Jing H
Int J Mol Med; 2015 Sep; 36(3):698-704. PubMed ID: 26133246
[TBL] [Abstract][Full Text] [Related]
11. Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.
Fan H; Lu X; Wang X; Liu Y; Guo B; Zhang Y; Zhang W; Nie J; Feng K; Chen M; Zhang Y; Wang Y; Shi F; Fu X; Zhu H; Han W
J Immunol Res; 2014; 2014():371087. PubMed ID: 24963497
[TBL] [Abstract][Full Text] [Related]
12. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
[TBL] [Abstract][Full Text] [Related]
13. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.
Stewart DJ; Issa JP; Kurzrock R; Nunez MI; Jelinek J; Hong D; Oki Y; Guo Z; Gupta S; Wistuba II
Clin Cancer Res; 2009 Jun; 15(11):3881-8. PubMed ID: 19470736
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
[TBL] [Abstract][Full Text] [Related]
15. The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
Gao D; Herman JG; Guo M
Oncotarget; 2016 Jun; 7(24):37331-37346. PubMed ID: 26967246
[TBL] [Abstract][Full Text] [Related]
16. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma.
Kristensen LS; Hansen JW; Kristensen SS; Tholstrup D; Harsløf LB; Pedersen OB; De Nully Brown P; Grønbæk K
Clin Epigenetics; 2016; 8(1):95. PubMed ID: 27610206
[TBL] [Abstract][Full Text] [Related]
17. Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length.
Carlund O; Thörn E; Osterman P; Fors M; Dernstedt A; Forsell MNE; Erlanson M; Landfors M; Degerman S; Hultdin M
Clin Epigenetics; 2024 May; 16(1):68. PubMed ID: 38773655
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation.
Liu J; Min S; Kim D; Park J; Park E; Koh Y; Shin DY; Kim TK; Byun JM; Yoon SS; Hong J
Clin Epigenetics; 2023 May; 15(1):75. PubMed ID: 37138342
[TBL] [Abstract][Full Text] [Related]
19. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.
Kalac M; Scotto L; Marchi E; Amengual J; Seshan VE; Bhagat G; Ulahannan N; Leshchenko VV; Temkin AM; Parekh S; Tycko B; O'Connor OA
Blood; 2011 Nov; 118(20):5506-16. PubMed ID: 21772049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
